Effectiveness of therapy with iloprost in hand-arm vibration syndrome

Occupational Medicine

Volumn 54, Issue 4, 2004, Pages 261-264

  Meloni, Michele ^a,c   Torrazza, Mario ^a   Ledda, Roberto ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c Dipartimento di Sanita Pubblica   (Italy)

Author keywords

Hand arm vibration syndrome; Iloprost; Prostacyclin; Vibration white finger

Indexed keywords

ANABOLIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOPROST; ILOPROST; NITRATE; PENTOXIFYLLINE; STANOZOLOL; VASODILATOR AGENT;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; FLUSHING; FUNCTIONAL DISEASE; HAND ARM VIBRATION SYNDROME; HEADACHE; HUMAN; HYPOTENSION; MALE; MICROCIRCULATION; NAUSEA; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; SIDE EFFECT; SKIN ULCER; SMOKING CESSATION; SMOKING HABIT; VASODILATATION; VASOSPASM; VIBRATION SYNDROME; VOMITING;

ARM; ARM INJURIES; HAND; HAND INJURIES; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; MICROCIRCULATION; MIDDLE AGED; OCCUPATIONAL DISEASES; TREATMENT OUTCOME; VASODILATOR AGENTS; VIBRATION;

EID: 3042773997     PISSN: 09627480     EISSN: None     Source Type: Journal    
DOI: 10.1093/occmed/kqh035     Document Type: Article

References (30)

1. Black CM, Halkier-Sorensen L, Belch JJF, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952-960.
2. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-2655.
3. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000;18:499-502.
4. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine Rheumatology 2001;40:1038-1043.
5. Belch JJF, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985;24:346-350.
6. Keller J, Kaltenecker A, Schricker KT, Neidhardt B, Hornstein OP. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. Arch Dermatol Res 1985;277:323-325.
7. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
8. Wigley FM, Korn HJ, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Arthritis Rheum 1998;41:670-677.
9. Cordioli E, Virgilio S, Ghirardi R, Martinelli M. Efficacia della terapia a lungo termine con iloprost sul fenomeno di Raynaud nella sclerosi sistemica progressiva. Minerva Med 1992;83:739-744.
10. Kyle MV, Belcher G, Hazelman BL. Placebo-controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-1406.
11. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-47.
12. Rademaker M, Thomas RH, Provost G, Beacham JA, Cooke ED, Kirby JD. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 1987;63:617-620.
13. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. Br Med J 1989;298:561-564.
14. Torley HI, Madhok R, Capell HA, et al. A double blind, randomized, multicentre comparison of two doses of intravenous iloprost and oral nifedipine in treatment of Raynaud's phenomenon secondary to connective tissue disease. Ann Rheum Dis 1991;50:800-804.
15. Watson HR, Belcher G. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 1991;50:359-361.
16. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-1413.
17. Yardumian DA, Isenberg DA, Rustin M, et al. Successful treatment of Raynaud's syndrome with iloprost a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-226.
18. Gemne G, Pykko I, Taylor W, Pelmear PL. The Stockholm Workshop Scale for the classification of cold-induced Raynaud's phenomenon in the hand-arm vibration syndrome (revision of the Taylor-Pelmear Scale). Scand J Work Environ Health 1987;13:275-278.
19. Meloni M, Casula D. Malattie da vibrazioni meccaniche. In: Casula D, ed. Medicina del Lavoro. Bologna: Monduzzi, 2003.
20. Creutzig A, Hiller S, Appiah R, Thum J, Caspary L. Nailfold capillaroscopy and laser Doppler fluxmetry for evaluation of Raynaud's phenomenon: how valid is the local cooling test? Vasa 1997;26:205-209.
21. Cleophas TJ, Niemeyer MG. Raynaud's syndrome, an enigma after 130 years. Angiology 1993;44:196-209.
22. Coffman JD. The enigma of primary Raynaud's disease. Circulation 1989;80:1089-1090.
23. Klippel JH. Raynaud's phenomenon: the French tricolor. Arch Intern Med 1991;151:2389-2393.
24. Spencer-Greene G. Outcomes in primary Raynaud phenomenon. A meta-analysis of the frequency, rates, and predictors of transition to secondary disease. Arch Intern Med 1998;158:595-600.
25. Cooke ED. Raynaud's syndrome. Thymoxamine, iloprost, and ACE inhibitors are among the effective treatments now available. Br Med J 1990;300:553-555.
26. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983;308:880-883.
27. Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo-controlled study. Ann Rheum Dis 1995;54:197-200.
28. Pelmear PL, Taylor W. Hand-arm vibration syndrome: clinical evaluation and prevention. J Occup Med 1991;33:1144-1149.
29. Belch JJF, Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996;52:682-695.
30. Helfman T, Falanga V. Stanazolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995;33:254-258.